Abstract
The major challenge facing the oncologist is how to treat cancer that has disseminated to and is growing in multiple organs throughout the body. Despite major advances in general patient care, surgical techniques, and adjuvant therapies, most deaths from cancer are caused by the growth of metastases that are resistant to chemotherapy or radiotherapy. A major factor which prevents treatment of metastases is the fact that cancer cells populating both primary and secondary neoplasms are biologically heterogeneous (1, 2). By the time of diagnosis, and certainly in clinically advanced lesions, malignant neoplasms contain multiple cell populations exhibiting a wide range of biological characteristics such as cell surface structures, growth rate, sensitivity to various cytotoxic drugs, and the ability to further invade and metastasize. The implication of the heterogeneous responses of tumor cells to conventional anticancer drugs is that the successful therapy of disseminated metastases must circumvent the problems of biologic heterogeneity and be a treatment modality to which resistance is unlikely to develop.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
I. J. Fidler and I. R. Hart, Biological diversity in metastatic neoplasms: Origins and implications. Science, 217, 998–1003 (1982).
I. J. Fidler and G. Poste, The cellular heterogeneity of malignant neoplasms: Implications for adjuvant chemotherapy. Semin. Oncol. 12, 207–222 (1985).
I. J. Fidler, Macrophages and metastases: A biological approach to cancer therapy. Cancer Res. 45, 4714–4726 (1985).
L. Chedid, L. Carelli, and F. Audibert, Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule. J. Reticuloendothel. Soc. 26, 631–641 (1979).
E. Lederer, Synthetic immunostimulants derived from the bacterial cell wall. J. Med. Chem. 23, 819–825 (1980).
W. E. Fogler and I. J. Fidler, Modulation of the immune response by muramyl dipeptide. In: Immune Modulation Agents and Their Mechanisms (M. A. Chirigos and R. L. Fenichel, Eds.), pp. 499–512. Marcel Dekker, New York, 1984.
I. J. Fidler, The MAF dilemma. Lymphokine Res. 3, 51–54 (1984).
I. Saiki and I. J. Fidler, Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages. J. Immunol. 135, 684–688, (1985).
I. Saiki, S. Sone, W. E. Fogler, E. S. Kleinerman, G. Lopez-Berestein, and I. J. Fidler, Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes. Cancer Res. 45, 6188–6193, (1985).
I. J. Fidler, W. E. Fogler, E. S. Kleinerman, and I. Saiki, Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human gamma interferon encapsulated in liposomes. J. Immunol. 135, 4289–4294, (1985).
J. B. Jr. Hibbs. Discrimination between neoplastic and nonneoplastic cells in vitro by activated macrophages. J. Natl. Cancer Inst. 53, 1487–1492, (1974).
C. D. Bucana, L. C. Hoyer, A. J. Schroit, E. S. Kleinerman, and I. J. Fidler, Ultrastructural studies of the interaction between liposomes-activated human blood monocytes and allogeneic tumor cells in vitro. Am. J. Pathol. 112, 101–111, (1983).
I. J. Fidler, Recognition and destruction of target cells by tumoricidal macrophages. Isr. J. Med. Sci. 14, 177–191, (1978).
I. J. Fidler and E. S. Kleinerman, Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J. Clin. Oncol. 2, 937–943, (1984).
W. E. Fogler and I. J. Fidler, Nonselective destruction,of murine neoplastic cells by syngeneic tumoricidal macrophages. Cancer Res. 45, 14–18, (1985).
G. Poste, R. Kirsh, W. Fogler, and I. J. Fidler, J. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. Cancer Res. 39, 881–892, (1979).
G. Poste and R. Kirsh, Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages. Cancer Res. 39, 2582–2590, (1979).
G. Poste, The tumoridal properties of inflammatory tissue microphages and multinucleate giant cells. Am. J. Pathol. 96, 595–606, (1979).
A. C. Allison, Mode of action of immunological adjuvants. J. Reticuloendothel. Soc. 26, 619–630, (1979).
A. J. Schroit and I. J. Fidler, Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res. 42, 161–167, (1982).
G. Poste, R. Kirsh, and P. Bugelski, Liposomes as a drug delivery system in cancer therapy. In: Novel Approaches to Cancer Chemotherapy (P. S. Sunkara, Ed.), pp. 166–221. Academic Press, New York, 1984.
A. J. Schroit, I. R. Hart, J. Madsen, and I. J. Fidler, Selective delivery of drugs encapsulated in liposomes: Natural targeting to macrophages involved in various disease states. J. Biol. Response Modif. 2, 97–100, (1983).
I. J. Fidler, Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science, 208, 1469–1471, (1980).
I. J. Fidler, S. Sone, W. E. Fogler, and Z. L. Barnes, Eradication of spontaneous metastases and activation of alveolor macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc. Natl. Acad. Sci. U.S.A. 78, 1680–1684, (1981).
S. D. Deodhar, B. P. Barna, M. Edinger, and T. Chiang, Inhibition of lung metastases by liposomal immunotherapy in a murine fibrosarcoma model. J. Biol. Response Modif. 1, 27–34, (1982).
G. Lopez-Berestein, L. Milas, N. Hunter, K. Mehta, D. Eppstein, M. A. VanderPas, T. R. Mathews, and E. M. Hersh, Prophylaxis and treatment with liposome-encapsulated 6-O-steroyl-N-acetyl muramyl-L-aminobutyryl-D-isoglutamine. Clin. Exp. Metastasis, 2, 366–367, (1984).
N. C. Phillips, M. L. Mora, L. Chedid, P. Lefrancier, and J. M. Bernard, Activation of tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl derivative. Cancer Res. 45, 128–134, (1985).
D. A. Eppstein, M. A. Van Der Pas, E. B. Fraser-Smith, C. G. Kurahara, P. L. Feigner, T. R. Matthews, R. V. Waters, M. C. Venuti, G. H. Jones, R. Metha, G. Lopez-Berestein, Liposome-encapsulated muramyl dipeptide analogue enhances non-specific host immunity. Int. J. Immunother. 2, 115–126, (1986).
J. E. Talmadge, B. F. Lenz, R. Klabansky, R. Simon, C. Riggs, S. Guo, R. K. Oldham, and I. J. Fidler, Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyltripeptide. Cancer Res. 46, 1160–1163, (1986).
S. Sone and I. J. Fidler, Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J. Immunol. 125, 2454–2460, (1980).
I. J. Fidler and A. J. Schroit, Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: In situ activation of macrophages and therapy of spontaneous cancer metastasis. J. Immunol. 133, 515–518, (1984).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Plenum Press, New York
About this chapter
Cite this chapter
Fidler, I.J. (1987). Circumvention of Biologic Diversity of Cancer Metastasis. In: Cerutti, P.A., Nygaard, O.F., Simic, M.G. (eds) Anticarcinogenesis and Radiation Protection. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6462-1_69
Download citation
DOI: https://doi.org/10.1007/978-1-4615-6462-1_69
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4615-6464-5
Online ISBN: 978-1-4615-6462-1
eBook Packages: Springer Book Archive